Oregon’s huge investments in substance use treatment beds began to pay off in 2025, when hundreds of new beds came online.

Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with ...

A sweeping bill would fund the VA to examine ketamine, magic mushrooms and other hallucinogens for potential medical use for ...

Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base ...

Kuwait is witnessing significant progress in combating drug abuse through an integrated health and legislative system that ...

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...

We are fighting for transparency, accountable science, and for the rights of the common people to receive informed consent.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

The latest announcement is out from Alkermes ( (ALKS) ).